Core Insights - Eupraxia Pharmaceuticals Inc. has introduced new pharmacokinetic data from its Phase 2a Eosinophilic Esophagitis program, highlighting the capabilities of its DiffuSphere™ platform for precise drug delivery [1][4][9] Group 1: DiffuSphere™ Technology - DiffuSphere™ enables targeted drug delivery with a flat, stable, and long-lasting release profile, minimizing adverse effects associated with conventional drug delivery methods [2][17] - The technology consists of a pure drug crystal encased in a polymer shell, allowing for controlled release and high concentrations in target tissues while reducing systemic exposure [3][17] - Clinical trials have demonstrated that a single injection of DiffuSphere™ can maintain therapeutic drug levels for over six months, significantly improving treatment outcomes for conditions like eosinophilic esophagitis and osteoarthritis [5][6] Group 2: Clinical Trial Results - In the RESOLVE trial, DiffuSphere™ showed a treatment duration exceeding six months with a steady drug level of 1.5 pg/ml maintained in patients receiving 4 mg of fluticasone propionate [5] - The Phase 2b study of EP-104IAR for osteoarthritis demonstrated significant pain relief for up to 22 weeks, with no adverse effects on blood glucose metabolism or adrenal function [6][12] - Eupraxia's clinical data supports the efficacy of DiffuSphere™ in improving key disease measures, including patient symptoms and tissue health [5][9] Group 3: Broader Applications - DiffuSphere™ has shown versatility across various drug classes and anatomical locations, including intraarticular, intraesophageal, and intravitreal applications [8][17] - The technology has been successfully tested with local anesthetics and anti-infective agents, indicating its potential for diverse therapeutic uses [8][17] - Eupraxia aims to leverage DiffuSphere™ for future treatments in oncology and infectious diseases, expanding its application beyond pain and inflammatory gastrointestinal diseases [17][18]

Core Insights - Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on optimizing drug delivery through its proprietary DiffuSphere™ technology, which addresses significant unmet medical needs [1][5] - The company will present a poster at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting, highlighting its research on EP-104IAR, a long-acting intra-articular injection for osteoarthritis [1][4] Company Overview - Eupraxia specializes in developing locally delivered, extended-release products aimed at therapeutic areas with high unmet medical needs [5] - The DiffuSphere™ technology is designed to facilitate targeted drug delivery, potentially improving safety, tolerability, efficacy, and duration of effect compared to traditional methods [5] Event Details - The ACR Convergence 2024 Annual Meeting will take place in Washington, D.C. from November 14-19, 2024, providing a platform for education and research in rheumatology [3] - Eupraxia's poster presentation will focus on the sustained improvement in pain for subjects with moderate baseline pain and BMI less than 30, based on a Phase 2 study [4]

Core Insights - Eosinophilic Esophagitis (EoE) is a rapidly increasing digestive disorder affecting over 450,000 people in the United States, leading to significant healthcare burdens and mental health issues [3][4]. Company Overview - Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing locally delivered, extended-release products to address high unmet medical needs [4]. - The company utilizes its proprietary DiffuSphere™ technology for optimized drug delivery, aiming to improve safety, tolerability, efficacy, and duration of effect for existing and novel drugs [4]. Product Development - Eupraxia's EP-104GI is currently in a Phase 1b/2a trial (RESOLVE trial) for treating EoE, utilizing a unique injection method for local drug delivery [5]. - The company has also completed a Phase 2b clinical trial (SPRINGBOARD) for EP-104IAR, targeting pain from knee osteoarthritis, achieving its primary endpoint and three of four secondary endpoints [5]. - Eupraxia is developing a pipeline of long-acting formulations for various indications, including inflammatory joint diseases and oncology [5]. Upcoming Events - Eupraxia's CEO, Dr. James A. Helliwell, will present at a Tribe Public Webinar on November 15, 2024, discussing EoE and its implications [1][2].

Core Insights - Eupraxia Pharmaceuticals Inc. announced positive clinical data from its RESOLVE Phase 1b/2a trial for EP-104GI, a treatment for eosinophilic esophagitis (EoE) [2][4] Group 1: Clinical Trial Results - In the fifth cohort of the RESOLVE trial, one patient achieved complete histological remission at 12 weeks, with a significant reduction in eosinophils [3] - All six evaluable patients in the fourth and fifth cohorts reported improved symptoms, with a 41% mean reduction in the Straumann Dysphagia Index (SDI) scores at 12 weeks [3][4] - The fourth cohort showed the largest average reduction in SDI scores to date, with a four-point reduction at 24 weeks [6] - The fifth cohort demonstrated the greatest percentage change in histology scores, with a peak reduction of 100% in Stage and Grade scores and a mean 54% reduction in Composite Stage and Grade scores [3][4] Group 2: Safety and Efficacy - No serious adverse events have been reported across all five cohorts, indicating a favorable safety profile for EP-104GI [3][4] - Plasma fluticasone levels remained predictable and well below those seen in daily fluticasone asthma treatments, with no adverse events such as candidiasis or adrenal suppression reported [4] - The trial is designed as a multicenter, open-label, dose-escalation study, assessing safety, tolerability, pharmacokinetics, and efficacy of EP-104GI [4][10] Group 3: Future Developments - Cohort 6 is fully enrolled and dosed, with 12-week data expected in Q1 2025 [3] - The company plans to periodically disclose additional data from the RESOLVE trial [5]

Exhibit 99.1 EUPRAXIA PHARMACEUTICALS INC. CONSOLIDATED FINANCIAL STATEMENTS For the Three and Nine Months ended September 30, 2024 (Unaudited and Expressed in U.S. Dollars) EUPRAXIA PHARMACEUTICALS INC. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS September 30, 2024 (Unaudited and Expressed in U.S. Dollars) CONTENTS | CONSOLIDATED BALANCE SHEETS | 2 | | --- | --- | | CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | 3 | | CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) | 4-5 | | CONSOL ...

Core Insights - Eupraxia Pharmaceuticals Inc. reported its financial results for Q3 2024, highlighting advancements in clinical trials and financial activities [1][2] Clinical Developments - The company advanced its Phase 1b/2a RESOLVE trial for EP-104GI, showing positive results for eosinophilic esophagitis and presenting data at international medical conferences [2][3] - The Phase 2b SPRINGBOARD trial data for EP-104IAR in knee osteoarthritis was published in The Lancet Rheumatology, indicating significant clinical progress [2][3] Financial Performance - Eupraxia incurred a net loss of $6.0 million for Q3 2024, an increase from $4.9 million in Q3 2023, primarily due to reduced other income from changes in financial instruments [4] - Cash reserves decreased to $8.7 million as of September 30, 2024, down from $19.3 million at the end of Q4 2023, with funds allocated for clinical trials and general corporate purposes [5] Funding and Future Outlook - The company raised C$44.5 million through a non-brokered private placement, which, along with existing cash reserves, is expected to fund operations through Q3 2026 [6] - As of September 30, 2024, the company had 35,622,553 common shares outstanding [6] Management Changes - The company strengthened its management team by appointing Dr. Amanda Malone as Chief Operating and Scientific Officer and Dr. Rahul Sarugaser as Executive Vice President of Corporate Development [3]

Exhibit 99.1 EUPRAXIA PHARMACEUTICALS INC. CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months ended June 30, 2024 (Unaudited and Expressed in U.S. Dollars) EUPRAXIA PHARMACEUTICALS INC. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2024 (Unaudited and Expressed in U.S. Dollars) | | Three months | | Three months | | Six months | | Six months | | --- | --- | --- | --- | --- | --- | --- | --- | | | ended June 30, | | ended June 30, | | ended June 30, | | ended June 30, | | | 2024 | | 2023 | | ...

Exhibit 99.1 Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial Results Victoria, B.C. - April 1, 2024 - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced its financial results (prepared in accordance with U.S. GAAP) and operational highlights for the fourth quarter ended December 31, 2023. All ...